Jefferies Group LLC reiterated their buy rating on shares of Zoetis Inc. (NYSE:ZTS) in a research note released on Friday morning. Jefferies Group also issued estimates for Zoetis’ FY2017 earnings at $2.39 EPS, FY2018 earnings at $2.79 EPS, FY2019 earnings at $3.21 EPS, FY2020 earnings at $3.63 EPS and FY2021 earnings at $4.00 EPS.
ZTS has been the subject of a number of other research reports. Zacks Investment Research upgraded shares of Zoetis from a hold rating to a buy rating and set a $71.00 price objective for the company in a report on Thursday, October 12th. Cantor Fitzgerald restated a buy rating and issued a $75.00 price objective on shares of Zoetis in a report on Wednesday, September 6th. BidaskClub cut shares of Zoetis from a hold rating to a sell rating in a report on Friday, October 6th. Morgan Stanley lifted their price objective on shares of Zoetis from $61.00 to $70.00 and gave the company an equal weight rating in a report on Friday, November 3rd. Finally, Goldman Sachs Group, Inc. (The) restated a neutral rating and issued a $62.00 price objective on shares of Zoetis in a report on Monday, August 7th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $67.06.
Shares of Zoetis (NYSE:ZTS) opened at $68.88 on Friday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. The firm has a market cap of $33,686.24, a PE ratio of 31.71, a price-to-earnings-growth ratio of 2.02 and a beta of 1.02. Zoetis has a 12-month low of $48.24 and a 12-month high of $70.48.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.63 by $0.02. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.52 earnings per share. equities research analysts anticipate that Zoetis will post 2.36 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Thursday, November 9th will be given a dividend of $0.105 per share. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $0.42 annualized dividend and a dividend yield of 0.61%. Zoetis’s dividend payout ratio is presently 22.11%.
Hedge funds have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. raised its position in Zoetis by 16.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after purchasing an additional 230 shares during the last quarter. Harfst & Associates Inc. raised its position in Zoetis by 16.1% in the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after purchasing an additional 260 shares during the last quarter. Almanack Investment Partners LLC. purchased a new stake in Zoetis in the 2nd quarter valued at $119,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in Zoetis by 251.9% in the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after purchasing an additional 1,360 shares during the last quarter. Finally, Peddock Capital Advisors LLC purchased a new stake in Zoetis in the 2nd quarter valued at $140,000. Hedge funds and other institutional investors own 92.44% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with our FREE daily email newsletter.